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Abstract 
Glioma models have provided important insights into human brain cancers. Among 
investigating tools, magnetic resonance imaging (MRI) has allowed their characterization and 
diagnosis. 
In this study, we investigated whether diffusion MRI might be a useful technique for early 
detection and characterization of slow-growing and diffuse infiltrative gliomas, such as the 
proposed new models, LN-2669GS and LN-2540GS glioma sphere xenografts. Tumours grown 
in these models are not visible in conventional T2-weighted and contrast-enhanced T1-weighted 
MRI at 14.1T. 
Diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI) protocols were 
optimized for contrast by exploring long diffusion times sensitive for probing the 
microstructural alterations induced in the normal brain by the slow infiltration of glioma sphere 
cells. 
Compared with T2-weighted images, tumours were properly identified in their early stage of 
growth using diffusion MRI, and confirmed by localized proton MR spectroscopy as well as 
immunohistochemistry. The first evidence of tumour presence was revealed for both glioma 
sphere xenograft models three months after tumour implantation, while no necrosis, oedema or 
haemorrhage were detected either by MRI or by histology. Moreover, different values of 
diffusion indices, such as mean diffusivity (MD) and fractional anisotropy (FA), were obtained 
in tumours grown from LN-2669GS and LN-2540GS glioma sphere lines, respectively. These 
observations highlighted diverse tumour microstructures for both xenograft models, which were 
reflected in histology. 
This study demonstrates the ability of diffusion MRI techniques to identify and investigate early 
stages of slow-growing, invasive tumours in the mouse brain, thus providing a potential imaging 
biomarker for early detection of tumours in humans. 
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INTRODUCTION 
Diffuse gliomas (WHO grade II to IV) (1) are the most common primary brain tumours in 
humans and one of the leading causes of cancer-related deaths in adults (2). Their diffuse 
infiltration into the surrounding normal brain precludes complete resection and they all 
eventually recur, usually having progressed to a more aggressive tumour. The infiltrative part 
will give rise to tumour recurrence even in MRI-controlled, macroscopically fully resected 
patients, since the extent of invasion is not visible using conventional T1 and T2-weighted MRI. 
Hence, it is difficult to target treatment to this “invisible” part. Among diffuse gliomas, 
glioblastoma (GBM, World Health Organization [WHO] grade IV) is the most aggressive form 
(3) with a median overall survival of only 14.6 months (4) despite multimodal treatment of 
maximal safe resection, followed by combined chemo-radiotherapy. Visualization of the 
infiltrative portion of gliomas is a necessary first step for testing novel treatment strategies 
affecting migrating tumour cells (5). 
Over the past decades, rodent models of diffuse infiltrative gliomas have been extensively 
investigated (6-8) to better understand the genetic and molecular pathology of malignant 
gliomas and to assess the efficacy of newer therapies (9). Although none of the existing models 
fully reflect the corresponding human neoplasm (7), their use in combination with advanced 
neuroimaging techniques (10-12) has led to the identification of imaging biomarkers for the 
detection of brain cancers and early prediction of therapeutic efficacy (13). 
MRI allows non-invasive in vivo monitoring of both tumour growth and response to therapy, 
and provides detailed structural information on tumour and brain tissue (14). Morphological 
features of diffuse gliomas, e.g. tumour location and size, necrosis, peritumoral oedema, 
heterogeneity, and haemorrhagic foci can be determined using routine contrast-enhanced T1-, 
and T2-weighted MRI. Nevertheless, conventional MRI has limited sensitivity and specificity in 
evaluating early therapeutic effects, in determining histological type and tumour grading and in 
accurately delineating tumour extent (15). Contrast-enhanced T1-weighted MRI tends to 
underestimate the diffuse infiltration of glioma cells (16) depending on the blood-brain-barrier 
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integrity at the infiltrative margins (17). In addition, histological correlation with T2-weighted 
images of gliomas has shown glioma-infiltrating cells beyond the hyper-intense region on T2-
weighted images (18). 
To overcome these limitations, advanced MRI methods sensitive to tissue properties related to 
brain cancer biology and glioma cell migration have been developed and implemented (14,19). 
Among these, diffusion MRI (20), which reflects information on the tissues microstructure, 
potentially allows imaging of glioma-infiltrating cells in the normal brain (21) and the detection 
of early changes in the tumour microenvironment following treatment (22). The diffusion-
weighted MR signal, which is recorded as a function of diffusion weighting or b-value, is 
affected by the complex composition and the geometric architecture of the investigated tissues. 
Due to the presence of structural barriers, water diffusion in brain tissue is restricted and/or 
hindered. Therefore, the diffusion time (Δ) becomes a key parameter for improving the 
sensitivity of diffusion MRI to tissue microstructure. For longer Δ, water molecules in the brain 
probe more obstacles and/or barriers over larger spatial scales, which are, however, smaller than 
the dimensions of a pixel. Moreover, with increasing Δ diffusion can be considered “quasi-
Gaussian” in normal physiological condition and the measured diffusion coefficient shows a 
rather monotonic behaviour as function of Δ and membrane permeability (23), which is more 
visible for shorter diffusion times (24). Therefore, the measured diffusion coefficient, which 
reflects tissue characteristics, might change with the tumour progression for longer Δ thus 
playing an important role to evaluate healthy and diseased tissues. To our knowledge, no 
previous studies have reported the effect of Δ on water diffusion in human glioma models, 
except an in vitro study on glioma cells (25). By increasing the diffusion time, water molecules 
probe a wider area of tissue in accordance to the relation (l = (2DΔ)1/2) between the diffusion 
distance (l) and the diffusion time (Δ). As a consequence, we hypothesise that the diffusion 
signal at extended Δ will be more sensitive to the small changes in cell density which are 
characteristic of the slow infiltration of gliomas. This feature is well modelled in the 
investigated xenografts.  
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Currently, DWI (26) and DTI (27-28) techniques are commonly used to investigate diffuse 
infiltrative gliomas in both preclinical (29-30) and clinical settings (31-32). These techniques 
allow the detection of the invasive pathways of glioma cell migration in the brain, which seem 
to preferentially occur along the myelinated fibres in white matter tracts (1,33). 
Using optimized diffusion protocols at 14.1T, the aim of this study was to identify slow-
growing glioma sphere xenografts in their early stages of growth, which are otherwise not 
visible using conventional Gd-DTPA enhanced T1-weighted (34) and T2-weighted MRI. In 
addition, differences in diffusion indices of LN-2669GS and LN-2540GS glioma sphere 
xenografts allowed the evaluation of differences in their microstructure. Tumour growth 
detected by diffusion methods was confirmed by localized proton MR spectroscopy (MRS) and 
immunohistochemistry. 
MATERIALS AND METHODS 
Glioma-derived sphere lines 
Two human glioma-derived sphere lines, LN-2540GS and LN-2669GS (35,36), were used for 
orthotopic xenografts in nude mice. As previously described (36), each line was derived by 
mechanical and enzymatic dissociations of GBM surgical specimens into a single cell 
suspension. After CD133 (Miltenyi Biotec) selection procedure, cells were cultured under stem 
cell conditions in DMEM-F12 medium (Invitrogen; 10565-018) supplemented with 2% of B27 
(Invitrogen; 17504), human recombinant epidermal growth factor (20 ng/mL) and human 
recombinant basic fibroblast growth factor (20 ng/mL) (Peprotech; AF-100-15 and 100-18B). 
Basic genetic characterization and authentication have been published previously (35,36). 
Animal Model 
Orthotopic human gliomas were induced in eight female athymic nude mice (Swiss nu/nu; 
Charles River France, France), aged 6-9 weeks and weighing 20-28g. All experimental 
procedures and animal care were performed according to the federal and local ethical guidelines 
and approved by the local veterinary authorities (VD 1181-5). Mice were anesthetized and 
placed into a stereotaxic frame (Stoelting Co., Wood Dale, IL, USA). Glioma sphere cells 
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(1×105), dissociated into a single cell suspension, were injected in a volume of 5 µl of PBS via a 
stereotaxic injector at a flow rate of 5 l/min (Quintessential Stereotaxic Injector (QSI)TM) into 
the right striatum of the mice (coordinates from bregma: 0.0 mm posterior, 2.5 mm lateral, 3.0 
mm ventral; n=4 per sphere line). 
Animal preparation for MRI 
Fifty days after orthotopic implantation of human glioma sphere cells, mice underwent MRI for 
the first time and then once a week. Control mice (n=4) were also investigated using the same 
MRI protocol. 
For MRI measurements, each mouse was anaesthetized with isoflurane (4% induction, 1.5-2% 
maintenance) in a mixture of air:O2 (1:0.5 l/min induction, 0.7/0.3 l/min maintenance), and 
placed in a home-built dedicated holder with the head stereotaxically fixed by ear pins and bite 
bar. Physiological monitoring was performed using an MRI-compatible small animal 
monitoring and gating system (Model 1025, SA Instruments, Stony Brook, NY, USA). The 
body temperature was maintained in the range 36.5 - 37.5 °C using a circulating warm water 
system and the respiratory rate kept between 60 and 90 bpm by regulating the isoflurane level. 
MR imaging 
All measurements were performed on a 14.1 T/26 cm horizontal bore magnet (Magnex 
Scientific, Oxford, UK) interfaced to a Direct Drive console (Varian Medical System, Palo Alto, 
CA, USA), and equipped with a 12-cm inner diameter actively-shielded gradient set (400 mT/m 
in 120 µs). A two-loop quadrature surface coil was used as a radio-frequency transceiver for 
MR imaging and spectroscopy. MRI protocol included T2-weighted images, DWI and DTI 
scans. After measuring scout scans, multi-slice T2-weighted fast spin-echo (TSE) images of 
mouse brain were acquired in the coronal orientation as an anatomical reference (TR/TEeff = 
5000/52 ms, echo train length = 8, field-of-view = 20 × 20 mm2, matrix size = 256 × 256, in-
plane resolution of 78 × 78 µm2, 13 slices of 0.6 thickness, 4 averages, scan time of 10 min). 
Static field homogeneity was optimized by adjusting all first and second order shims using an 
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EPI version of FASTMAP (37), resulting in water linewidths of 18-24 Hz over the selected 
volume of interest (6 × 5 × 4.5 mm3) centered in the mouse brain. 
Diffusion-weighted images of mouse brain were acquired in the coronal orientation using a 
pulse gradient stimulated echo (PGSTE) sequence (38) (TR/TE = 4000/22 ms; field-of-view = 
20 × 10 mm2, matrix size = 128 × 64, in-plane resolution = 156 × 156 µm2, 8 slices of 1 mm 
thickness sufficient to cover the whole tumour and the peritumoral areas, 2 averages, scan time 
of 67 min).  
To optimize DWI and DTI protocol for glioma detection, a pilot study was carried out on mice 
with LN-2540GS xenograft at early stages of tumour development by exploring several 
diffusion times (Δ = 40, 60, 80, 100, 150, 220 ms) with gradient duration (δ) equal to 4ms. For 
each Δ, DWI data were acquired using eight b-values (294, 389, 542, 754, 1024, 1352, 2185, 
2688 s/mm2) with the diffusion gradient applied along the readout direction (X-axis). The 
corresponding gradient amplitudes are summarized in Table 1. It is of note that the calculation 
of b-values includes the contribution of imaging and crusher gradients which lead to b0-values 
for the un-weighted diffusion images, as reported in Table 1. Contrast-to-noise ratio (CNR) of 
tumour was calculated for each DW image (acquired at each specified Δ and b-value) as the 
difference between the mean signal from regions-of-interest (ROIs) drawn (as circular areas of 
the same size) in the contralateral (CL) area, <CL>, and in the tumour (T), <T>, divided by the 
standard deviation of the signal in the CL region, σ(CL), [CNR = (<CL>-<T>)/ σ(CL)] (Table 
2). Signal-to-noise ratio (SNR) of tumour was determined for each Δ on the b0 image as the 
mean signal intensity of a ROI drawn in the tumour location (<T>) divided by the standard 
deviation (σ) of a large ROI in the background noise (N), that was visually devoid of artefacts 
[SNR = <T>/σ(N)]. 
Following the observation in this pilot study, the main DWI protocol for both glioma sphere 
derived xenografts, LN-2669GS and LN-2540GS, used Δ = 80ms with all the above-specified b-
values, which was justified by the pilot study CNR data (Table 2, Fig.1). The same DWI 
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protocol was also carried out with diffusion gradients applied along the phase encoding (Y-axis) 
and the slice selection (Z-axis) directions.  
CNR of tumour growing from both glioma sphere xenografts was also determined for Δ = 80 ms 
as function of b-values for the DWI data acquired during the last MRI session. 
DTI data were collected by acquiring seven images, one b0 image (no diffusion weighted, b = 0 
s/mm2) and six diffusion-weighted images, each of them with the same b-value of 1352 s/mm2, 
(which was found to provide the best tumour contrast by exploring different Δ and b-values in 
DWI scans as shown in Table 2) and encoding gradients applied in six unique orientations 
([1,0,0], [0,1,0], [0,0,1], [1/√2,1/√2,0], [1/√2,0,1/√2], [0,1/√2,1/√2]). The acquisition time was 
58 min. 
Apparent diffusion coefficient (ADC) maps of mouse brain were computed by fitting, voxel-by-
voxel, the signal intensity of the diffusion-weighted images as a function of b-values (S(b) = 
S(0) exp (-b·ADC)). 
Diffusion tensor maps, MD and FA maps, which reflect respectively the average diffusivity and 
the degree of anisotropy in each voxel (27), were computed by reconstructing the tensor. All 
diffusion maps, ADC, MD and FA, were computed using FSL DTIFIT routine (FSL, version 4 
software; http://www.fmrib.ox.ac.uk/fsl). 
ROIs containing the tumour, a CL area, and the corresponding brain regions of controls were 
drawn (as circular areas of the same size) on the ADC, MD and FA maps with reference to the 
diffusion-weighted image with Δ = 80ms, b = 1352 s/mm2, where tumour showed better contrast 
(Table 2). The CL area was selected considering the brain region symmetric to the tumour 
location with respect to the mid-sagittal plane. Mean values of ADC, MD and FA were 
calculated in the selected ROIs using a custom Matlab script. 
Statistically significant difference between the mean values of diffusion indices calculated in the 
selected ROIs of all tumour slices in all mice and in the corresponding CL was accepted for P < 
0.05, as determined with a two-tailed, paired Student’s t-test. Comparison between the diffusion 
10 
 
indices calculated in the tumour of both xenografts as well as the comparison between the 
diffusion indices calculated in the tumour of each xenograft and in the corresponding brain 
region of the control group were considered as statistically significant for P < 0.05, as 
determined with a two-tailed, unpaired Student’s t-test. 
MR spectroscopy 
Spectra of gliomas were acquired during the final MRI session in each mouse. Proton spectra 
were collected using a short echo-time (TE = 2.8 ms) spin echo, full intensity acquired localized 
(SPECIAL) (39) spectroscopy sequence from a VOI (2 × 2 × 2 mm3) located within the tumour, 
based on coronal diffusion-weighted images. Before measurements, field homogeneity was 
adjusted in the selected VOI, as mentioned above. Outer volume suppression interleaved with a 
VAPOR (variable power and optimized relaxation delays) (40) water signal suppression was 
used. Spectra were acquired with TR = 4000 ms, 15 blocks of 16 transients (total scan time 16 
min), spectral width of 7 kHz using 4096 data points. Each block was corrected for static field 
drift and summed for further analysis. Spectra from brain regions of healthy mice matching 
tumour size and location in the brain of injected mice were acquired for comparison. 
Metabolite concentrations were quantified by LCModel (41) and absolute concentration of 
metabolites were calculated using an unsuppressed water peak as a reference.  
Statistically significant levels were accepted for P<0.05, as determined with a two-way 
ANOVA followed by the Bonferroni multi-comparison post-tests. 
Immunohistochemistry 
All mice were sacrificed approximately 5 months after implantation, when gliomas were 
sufficiently large (maximum dimension of 2 - 3 mm) in DW images. Brains were dissected, 
fixed in formalin (4% buffered formalin) and embedded in paraffin. Tissue sections (5 μm) were 
stained with H&E (hematoxylin and eosin) or immunostained for the following proteins: GFAP 
(glial fibrillary acidic protein; G3893, Sigma), MIB-1 (MAB, DAKO M7240), p53 (MAB, 
DAKO, M7001) (37), using standard procedures (VENTANA), and human nucleolin (hNCL, 
1:200, 4°C, overnight; ab13541, abcam; does not react with mouse). For hNCL, the antigen 
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retrieval procedure in citrate phosphate buffer (pH 6.0) was performed at 95°C for 60 min 
followed by 8 min at 120°C (pressure cooker) and an additional blocking step of 15 min with 
Rodent Block M (cat # RBM 961, Biocare Medicale, Concorde, CA, USA) was added to the 
standard procedure. Immunoreactivity was visualized using DAB (diaminobenzidine 
tetrahydrochloride). 
RESULTS 
MRI results 
The diffusion time Δ = 80 ms was found to be optimal for identifying the glioma sphere 
xenografts as shown from the pilot study CNR data (Table 2, Fig. 1). The extension of the 
lesions was not properly visualised using lower diffusion times whereas higher Δ led to 
unacceptably low SNR. 
Tumours grown as LN-2669GS and LN-2540GS glioma sphere xenografts in mouse brain were 
detected for the first time three months after glioma implantation as shown in Fig. 2 and Fig. 3, 
respectively. Each of both figures shows typical T2-weighted and diffusion-weighted images 
(Fig. 2a, b and Fig. 3a, b) acquired three months after cell injection and the calculated ADC, and 
DTI maps (Fig. 2c-f, Fig. 3c-f) of a coronal slice from the mouse brain with LN-2669GS NCH-
1364 and LN-2540GS NCH-1365 glioma sphere xenograft, respectively.  
In both figures, the hypo-intense region on the diffusion-weighted images (Fig. 2b, 3b), which is 
just visible for the LN-2669GS NCH-1364 xenograft (Fig. 2b), and the corresponding hyper-
intense area on the ADC and MD maps (Fig. 2c-d, Fig. 3c-d) as well as the hypo-intense region 
on the FA map (Fig. 2e, Fig. 3e) shows the extent of the tumour. In contrast, no lesion is visible 
on the T2-weighted images (Fig. 2a, Fig. 3a). 
Fig. 4 and Fig. 5 show coronal T2-weighted and diffusion-weighted images (Fig. 4a, b and Fig. 
5a, b) acquired five months after injection of the cells as well as the computed ADC and DTI 
maps (Fig. 4c-f, Fig. 5c-f) from the mouse brain of the same mice displayed in Fig. 2 and Fig. 3, 
respectively. As with Fig. 2 and Fig. 3, both xenografts are visible in the diffusion-weighted 
images (Fig. 4b, Fig. 5b) as well as in the ADC (Fig. 4c, Fig. 5c) and DTI maps (Fig. 4d-f, Fig. 
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5d-f) whereas no evidence of tumour is seen in the corresponding T2-weighted image (Fig. 4a, 
Fig. 5a). 
Compared to Fig. 2 and Fig. 3, tumours grown from both sphere lines are more visible in Fig. 4 
and Fig. 5, at five months after cell injection due to tumour development. 
Fig. 6 shows DWI acquisition on the mouse brain comprising the LN-2540GS xenograft NCH-
1365 (A) as well as the CNR data for both xenografts (B). All data were acquired during the last 
MRI session. 
The progression of diffusion-weighted images (Fig. 6A, a-h), acquired two weeks after those 
presented in Fig. 5, demonstrates an improved delineation of tumour margins when the b-value 
increases. In particular, the lesion becomes visible when b is higher than 500 s/mm2 (Fig.6A, c) 
and the higher the b-value, the more noticeable the tumour (Fig. 6A, c-h), which appears as a 
hypo-intense lesion on the diffusion-weighted images (Fig. 6A, c-h) and as a hyper-intense area 
in the corresponding ADC map (Fig. 6A, k). Conversely, the lesion is not visible on the T2-
weighted image (Fig. 6A, j) that shows only a ventricular enlargement, as in Fig. 5a.  
The CNR data shown in Fig. 6B are displayed as a function of b-values (Δ = 80ms) for images 
acquired in the last MRI session (Fig. 4 and Fig. 6A, respectively). The best tumour contrast is 
given for both xenografts at a b-value equal 1352 s/mm2, the same given by the pilot study CNR 
data (Table 2). 
Mean values of the diffusion indices calculated in the tumour (T) and in the corresponding 
contralateral (CL) area of each xenograft as well as in the same brain regions of controls are 
summarized in Table 3 and Table 4 for both xenografts at early stages of tumour development 
(three months after injection) and at five months after cell injection, respectively. 
For both stages of tumour growth, either three months or five months after cell injection (Table 
3 and Table 4, respectively), a significant increase in MD was observed in tumours grown as 
LN-2669GS xenografts than in those grown from LN-2540GS cells compared to the CL area 
and to the values obtained from the same brain regions of controls. On the other hand, a 
significant decrease in FA was observed in both cases (Table 3 and Table 4) in tumours grown 
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as LN-2669GS xenograft whereas no changes were observed in those grown from LN-2540GS 
cells compared with the CL area and the control. Moreover, ADC values increased similarly in 
tumours grown from each xenograft (LN-2669GS or LN-2540GS xenografts), either at three or 
five months after cell injection (Table 3 and Table 4, respectively), compared with those in the 
contralateral area and in the controls.  
By comparing the corresponding values of the diffusion indices for each stage of tumour 
development, either three months (Table 3) or five months after cell injection (Table 4), the 
diffusion indices are slightly lower at earlier stages of tumour growth (Table 3). However, no 
significant difference was found between each corresponding diffusion indices in the two 
investigated stages of tumour development. 
MR Spectroscopic results 
Proton spectra were measured immediately before sacrificing mice for histological assessment. 
In Fig. 7, 1H spectra of a mouse brain from a control (Fig. 7a), LN-2669GS xenograft NCH-
1364 (Fig. 7b) and LN-2540GS xenograft NCH-1365 (Fig. 7c) are shown. 
The spectra of tumours (Fig. 7b - c) were acquired 5 months after injection of glioma sphere 
cells and compared with the control spectrum (Fig. 7a). The main changes in metabolite 
concentrations (indicated by arrows) are depicted in Fig. 7 and Fig. 8.  
In particular, the tumour grown from the LN-2669GS sphere line (Fig. 7b) showed a decrease in 
NAA (4.7mol/g vs. 7.7±0.4mol/g in controls, p<0.01), Glu (4.7mol/g vs. 8.4±0.4mol/g, 
p<0.001), NAA+NAAG (5.7mol/g vs. 8.6±0.4mol/g, p<0.01) and Glu+Gln (8.2mol/g vs. 
10.8±0.4mol/g, p<0.05) concentrations and an increase in Ins (10.8mol/g vs. 4.3±0.4mol/g 
p<0.0001) and Glc (4.7mol/g vs. 1.5±0.3mol/g, p<0.01) ones (solid black bars, Fig. 8).  
The tumour grown from the LN-2540GS sphere line (Fig. 7c) showed a more profound 
reduction in NAA (1.8mol/g vs. 7.7±0.4mol/g in controls, p<0.0001), Glu (3.7mol/g vs. 
8.4±0.4mol/g, p<0.0001), NAA+NAAG (2.6mol/g vs. 8.6±0.4mol/g, p<0.0001) and 
Glu+Gln (6.2mol/g vs. 10.8±0.4mol/g, p<0.0001) concentrations and an increase in the Ins 
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(15.0mol/g vs. 4.3±0.4mol/g p<0.0001) and Glc (6.4mol/g vs. 1.5±0.3mol/g, p<0.0001) 
with additional changes in Gly (5.0mol/g vs. 1.2±0.1mol/g, p<0.001) and Tau (5.7mol/g 
vs. 12.6±1.1 mol/g, p<0.0001), when compared to the LN-2669GS sphere line (solid gray bars,  
Fig. 8). 
Immunohistochemical results 
In order to assess imaging and spectroscopic results, histological and immunohistochemical 
analysis was performed on each mouse. Due to the highly invasive nature of the human LN-
2669GS cells, the intracerebral lesion was not visible on the H&E section (Fig. 9a). The human 
nucleolin (NCL) immunostaining (Fig. 9c - d) identifies the human tumour cells, and visualizes 
the infiltrative growth pattern of the human LN-2669GS tumour cells. GFAP expression 
indicated a region with enhanced gliosis that reached over to the co-lateral side probably 
induced by tumour cell infiltration (Fig. 9b). The area with strongest gliosis, as indicated by 
GFAP expression, shown in Fig. 9b, correlates with the hypo-intense region in the diffusion-
weighted image (Fig. 4b), the hyper-intense areas in the ADC and MD maps (Fig. 4c - d) and 
the hypo-intense regions in the FA map (Fig. 4e). Images shown in Fig. 4 as well as the 
spectrum displayed in Fig. 7b were all acquired during the last MRI session, immediately before 
euthanizing the mouse.  
The LN-2540GS xenograft comprises a compact and a more invasive component visualized on 
the H&E (Fig. 9e) and the GFAP immunostained (Fig. 9f) coronal section as well as by the 
nuclear expression of TP53 (not shown), which is detected in all tumour cells in agreement with 
hNCL staining (Fig. 9g). The high cell density in the compact tumour area is visualized in Fig. 
9g. The tumour area visible in Fig. 9e – g correlates with the hypo-intense regions visible on the 
DWI acquisition (Fig. 6c – h) and the hyper-intense area shown in Fig. 6k. Images shown in 
Fig. 6A and the spectrum reported in Fig. 7c were all acquired during the last MRI session, 
immediately before the mice were euthanized. 
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It is of note, the two xenografts display a striking difference in cell density, as visualized in Fig. 
9d and Fig. 9h, displaying at high magnification an area of human tumour cells (with the same 
magnification): LN-2669GS xenograft (Fig. 9d) shows a lower tumour cell density than LN-
2540GS xenograft (Fig. 9B, d).  
In addition, none of the histological sections of both xenografts shows any areas of necrosis, in 
accordance with imaging results. 
Discussion 
We have developed a diffusion MR protocol at 14.1T for early detection and investigation of 
human glioma xenografts in mice. Its performance was documented on human glioma 
xenografts derived from the sphere lines LN-2540GS and LN-2669GS, characterized by their 
slow and diffuse infiltrative growth in the mouse brain (8). With the optimized acquisition 
parameters of the diffusion-weighted stimulated-echo (PGSTE) sequence, in particular the 
diffusion time (Δ = 80 ms), the protocol allowed a proper detection and investigation of both 
xenograft models in the regime of hindered diffusion.  
Different diffusion times (Δ = 40-220ms) were explored in a pilot study carried out on LN-
2540GS glioma sphere xenografts at early stages of growth and the best tumour contrast was 
found for Δ = 80ms (Table 2). By selecting this observation time, the diffusion distance (l ~ 10 
µm) was comparable with the average distance between glioma sphere cells, which were not 
densely packed within the investigated xenografts due to their diffuse infiltrative growth. 
Therefore, shorter Δ do not give a proper tumour contrast whereas Δ = 80ms, by probing the 
distance between glioma sphere cells, optimizes tumour contrast for the investigated xenografts. 
Different diffusion properties due to diverse tumour microstructure in each model were also 
demonstrated by the calculated diffusion indices. Finally, presence of the tumours was 
confirmed by localized spectroscopy and by immunohistochemical analysis, which also 
provided information on morphologic tumour properties. 
As it is well known (38), the advantage of the PGSTE sequence is the use of long diffusion 
times avoiding signal loss due to the transverse relaxation time T2. On the other hand, its main 
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disadvantage is a loss of 50 % of the MR signal (42). We partly compensated this loss by using 
the shortest possible TE (22 ms), an ultra-high magnetic field and a small surface coil 
(dimensions of 21mm x 14 mm). However, the increase in SNR due to the high magnetic field 
was reduced by shorter transverse relaxation time T2. In addition, larger susceptibility effects 
due to the high magnetic field made the detection of glioma sphere xenografts even more 
challenging. 
Tumours grown in both xenograft models were not visible on T2-weighted images (Fig. 2a,3a, 
4a, 5a and 6j) even though a ventricular enlargement indicating tumour presence was observed 
on the T2-weighted image (Fig. 6) of the mouse brain with the LN-2540GS xenograft. Detection 
of slow-growing tumours from glioma-initiating cells was also difficult using contrast-enhanced 
T1-weighted MRI (34). 
During investigation of glioma sphere xenografts by means of diffusion MRI, the first evidence 
of tumour presence on diffusion-weighted images was revealed three months after glioma 
sphere cell injection for both xenograft models (Fig. 2 and Fig. 3). The absence of signs of 
necrosis and haemorrhagic foci in MR images, which was confirmed by histology, underlined 
the problematic detection of these slowly growing tumours using standard MRI techniques. 
Different diffusion properties between glioma xenografts grown from LN-2669GS and LN-
2540GS, respectively, were observed at three months (Table 3) and five months after cell 
injection (Table 4). At both time points, the larger MD in the LN-2669GS tumour model 
indicates that water molecules diffuse faster in tumours grown as LN-2669GS xenograft than in 
those grown from LN-2540GS cells that, in addition to the infiltrative part comprises a compact 
tumour component. Faster diffusion behaviour in the tumour grown from LN-2669GS 
compared to LN-2540GS is likely explained by the much lower cell density of the former (Fig. 
9d, Fig. 9h). Moreover, the reduced FA in the LN-2669GS model suggests loss of anisotropy in 
this tumour compared to the one grown from LN-2540GS cells, indicating a looser and less 
anisotropic tumour microstructure in the LN-2669GS engraft, which is also in accordance with 
histology. However, the six gradient orientations used in this study, as described in the method 
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section, do not provide an optimal sampling scheme for obtaining detailed information from the 
FA maps. 
The growth properties of the glioma sphere cell line derived xenografts in this study were highly 
invasive without formation of central necrosis. These properties allowed the investigation of 
invasive tumour characteristics which are a major diagnostic problem in patients with GBM and 
low grade gliomas to determine the extent of the tumour requiring treatment. Thus, our imaging 
results suggest that diffusion techniques can be more successful than standard T2-weighted MR 
images in detecting infiltrative tumours growing slowly as xenografts in mouse brain.  
The comparison between 1H spectra of both the investigated xenograft models shows more 
pronounced changes in absolute metabolite concentrations in tumours derived from LN-2540GS 
than in those from LN-2669GS sphere line (Fig. 7 and Fig. 9). This may be explained by 
different characteristics of these tumours. Since spectra of both xenografts were measured at the 
same time point after cell injection (5 months), the spectral profile of tumours grown from LN-
2540GS sphere line may indicate faster growing tumours compared with those grown as LN-
2669GS xenograft. The diffusion results support this finding as shown by comparing MR 
images between both xenografts at three months (Fig. 2 and Fig. 3, respectively) and five 
months after cell injection (Fig. 4 and Fig. 5). Moreover, the faster growing tumours, LN-
2540GS xenografts, are characterized by a lower MD compared to that of LN-2669GS 
xenografts. This is consistent with a more compact tumour for LN-2540GS xenograft compared 
to that grown from LN-2669GS sphere lines, which is in accordance with tumour histology. 
Conclusion 
In vivo measurements performed in this study showed that diffusion MRI technique is a useful 
method to detect and follow slowly growing, diffuse infiltrative tumours in the mouse brain. 
Imaging data in combination with localized proton spectra of lesions and immunohistochemical 
assessment demonstrated that the optimized diffusion MRI protocol can be useful in early 
detection of slow-growing human glioma xenografts as well as in the investigation of diffusion 
properties of tumours during their growth. Moreover, the calculated diffusion indices in the 
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tumours reflected microstructural differences between LN-2669GS and LN-2540GS xenografts, 
confirmed by histology. The diffusion parameters measured at a moderately long diffusion time 
(i.e. Δ = 80 ms) can be considered as potential biomarkers for early detection of diffuse 
infiltrative gliomas in humans due to the possible implementation of the proposed protocol on 
the clinical MR scanners. 
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b values 
[s/mm2] 
G [G/cm] 
Δ = 40ms Δ = 60ms Δ = 80ms Δ = 100ms Δ = 150ms Δ = 220ms 
294 4.6 2.0 0.0 - - - 
389 6.0 3.6 1.8 0.2 - - 
542 7.8 5.4 3.6 2.3 - - 
754 9.7 7.3 5.4 4.1 1.6 - 
1024 11.9 9.4 7.2 5.9 3.5 1.3 
1352 14.0 11.4 9.0 7.5 4.6 2.4 
2185 19.1 15.8 12.6 10.4 7.8 5.0 
2688 21.3 17.4 14.4 12.2 9.0 5.8 
 
Table 1. DWI protocol used to optimize tumour visualization. 
Summary of diffusion gradient amplitudes (G) corresponding to each b value and diffusion time (Δ) used in 
the DWI acquisition. 
 
A missing value (-) means b0 value higher than the considered b-values (b0 = 381, 590 and 884 s/mm2 for Δ = 
100, 150 and 220ms, respectively). 
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b values 
[s/mm2] 
CNR 
Δ = 40ms Δ = 60ms Δ = 80ms Δ = 100ms Δ = 150ms Δ = 220ms 
294  -0.43 ± 0.08 0.16 ± 0.04 0.54 ± 0.10 - - - 
389 0.53 ± 0.02 0.87 ± 0.04 1.01 ± 0.15 0.88 ± 0.09 - - 
542 0.52 ± 0.04 0.94 ± 0.12 1.61 ± 0.08 1.46 ± 0.12 - - 
752 1.22 ± 0.07 1.44 ± 0.09 1.63 ± 0.09 1.66 ± 0.06 1.44 ± 0.04 - 
1024 1.34 ± 0.09 1.72 ± 0.06 2.05 ± 0.07 1.89 ± 0.05 1.55 ± 0.08 1.31 ± 0.08 
1352 1.51 ± 0.12 1.84 ± 0.10 2.36 ± 0.12 2.04 ± 0.11 1.83 ± 0.13 1.47 ± 0.12 
2185 0.98 ± 0.09 1.43 ± 0.09 1.98 ± 0.10 1.24 ± 0.23 1.01 ± 0.09 0.86 ± 0.25 
2688 0.71 ± 0.10 1.01 ± 0.08 1.44 ± 0.09 0.80 ± 0.16 0.37 ± 0.09 -0.16 ± 0.03 
 
Table 2.  Summary of CNR determined from DW images acquired with different Δ and b-values from mouse brain 
with slow growing and highly infiltrative tumour at early stage of growth.  
 
All values are (mean ± SD). 
A missing value (-) indicates no DW images available for the evaluation of the CNR.  
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Table 3. Summary of ADC values, FA and MD indices of tumour (T) and contralateral (CL) area of both 
LN-2669GS and LN-2540GS xenografts at early stages of tumour development (3 months after cell 
injection).  
ADC values and DTI indices obtained from the corresponding brain regions of the control group are 
also reported. Data are mean ± 1 s.e.m. 
 LN-2669GS xenograft LN-2540GS xenograft 
Control* 
T CL T CL 
ADC 
[10-3mm2/s] 
0.65 ± 0.04¶¥ 0.53 ± 0.06 0.64 ± 0.02¶¥ 0.54 ± 0.05 0.56 ± 0.02 
FA 
 
   0.15 ± 0.03# 0.18 ± 0.04  0.19 ± 0.03 0.18 ± 0.03   0.18 ± 0.05 
MD 
[10-3mm2/s] 
  0.69 ± 0.07¶¥# 0.58 ± 0.05 0.64 ± 0.05¶¥ 0.58 ± 0.03 0.58 ± 0.03 
 * Control data were computed from regions corresponding to tumour location, symmetrically in both 
hemispheres. Statistics: ¶ significantly different from CL area in the same group (paired two-tailed t 
test, p < 0.01); ¥ significantly different from the related brain regions in the controls (unpaired two-
tailed t test, p<0.01), # significantly different from the corresponding value in tumour grown as LN-
2540GS xenograft. 
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 LN-2669GS xenograft LN-2540GS xenograft 
Control* 
T CL T CL 
ADC 
[10-3mm2/s] 
  0.67 ± 0.07¶¥ 0.53 ± 0.07 0.65 ± 0.04¶¥ 0.54 ± 0.05 0.54 ± 0.02 
FA 
 
  0.16 ± 0.02#¶¥ 0.19 ± 0.02  0.20 ± 0.03 0.19 ± 0.02 0.19 ± 0.02 
MD 
[10-3mm2/s] 
0.71 ± 0.04#¶¥ 0.57 ± 0.04 0.66 ± 0.05¶¥ 0.56 ± 0.03 0.57 ± 0.03 
 
Table 4. Summary of ADC values, FA and MD indices of tumour (T) and contralateral (CL) area of both 
LN-2669GS and LN-2540GS xenografts at 5 months after cell injection.  
ADC values and DTI indices obtained from the corresponding brain regions of the control group are 
also reported. Data are mean ± 1 s.e.m. 
* Control data were computed from regions corresponding to tumour location, symmetrically in both 
hemispheres. Statistics: ¶ significantly different from CL area in the same group (paired two-tailed t 
test, p < 0.01); ¥ significantly different from the related brain regions in the controls (unpaired two-
tailed t test, p<0.01), # significantly different from the corresponding value in tumour grown as LN-
2540GS xenograft. 
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Figure Captions 
Figure 1. In vivo MRI of LN-2540GS glioma sphere xenograft, 80 days after cell injection 
(pilot study data). Diffusion-weighted images of a mouse brain with LN-2540GS glioma sphere 
xenograft acquired with different diffusion times (Δ = 40, 60, 80, 100, 150, 220 ms) and same b-
value (1352 s/mm2). Image (c) shows a slightly better tumour contrast compared to others. 
Figure 2. In vivo MRI of LN-2669GS glioma sphere xenograft, three months after cell 
injection. Upper panel: coronal T2-weighted (a) and diffusion-weighted (b) images of the mouse 
brain with LN-2669GS xenograft NCH-1364, and the calculated ADC (c) map. Lower panel: 
corresponding diffusion tensor maps, MD (d), FA (e) and FA-modulated directionally encoded 
colour DEC (f) maps. The lesion (arrow) is barely visible on the diffusion-weighted image (b), 
ADC (c) and DTI maps.  
Figure 3. In vivo MRI of LN-2540GS glioma sphere xenograft, three months after injection of 
the cells. Upper panel: coronal T2-weighted (a) and diffusion-weighted (b) images of the mouse 
brain with LN-2540GS xenograft NCH-1365, and the calculated ADC (c) map. Lower panel: 
corresponding diffusion tensor maps, MD (d), FA (e) and FA-modulated DEC (f) maps. The 
lesion (arrow) is visible on the diffusion-weighted image (b), ADC (c) and DTI maps. 
Figure 4. In vivo MRI of LN-2669GS glioma sphere xenograft, five months after injection of 
the cells. Upper panel: coronal T2-weighted (a) and diffusion-weighted (b) images of the mouse 
brain with LN-2669GS xenograft NCH-1364, and the calculated ADC (c) map. Lower panel: 
corresponding diffusion tensor maps, MD (d), FA (e) and FA-modulated DEC (f) maps. Lesion 
(arrow) is visible on the diffusion-weighted image (b), ADC (c) and DTI maps. Due to the 
highly invasive and diffuse character of this tumour (corresponding histology, Fig. 9) it is 
difficult to delineate tumour borders. 
Figure 5. In vivo MRI of LN-2540GS glioma sphere xenograft, five months after injection of 
the cells. T2-weighted (a) and diffusion-weighted (b) images, MD (b), FA (c) and FA-modulated 
DEC maps of a coronal slice from the mouse brain with the LN-2540GS xenograft NCH-1365. 
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MD, FA and DEC maps, computed after DTI reconstruction, show a lesion (indicated by 
arrow). 
Figure 6. In vivo MRI of LN-2540GS glioma sphere xenograft (A) and CNR data of both 
xenografts (B), all acquired during the last MRI session (five months after injection of the cells). 
(A) Left panel: coronal diffusion-weighted images (a – h) of the mouse brain with LN-2540GS 
xenograft NCH-1365. Images are related to the DWI acquisition with b-values increasing along 
the read-out direction. Right panel: corresponding anatomical T2-weighted image (j) and ADC 
map (h) of glioma-bearing xenograft. Images were acquired 15 days after those shown in Fig. 5. 
Lesion (indicated by arrow and delineated by a dotted line in (g)) is visible on the diffusion-
weighted images (c – h) and the ADC map. 
(B) The CNR data of LN-2669GS xenograft NCH-1364 and LN-2540GS xenograft NCH-1365 
as function of b-values obtained in the last MRI session. 
Figure 7. 1H spectra of the brain from a control mouse (a) and from a tumour derived from LN–
2669GS, xenograft NCH-1364 (b) and a tumour derived from LN–2540GS, xenograft NCH-
1365 (c). Spectrum (b) and (c) were acquired 5 months after cells injection. Spectra were 
displayed with a Gaussian filter (0.11). 
Figure 8. Absolute metabolite concentrations in the tumours grown from LN-2669GS and LN-
2450GS sphere lines as well as in the same brain region of control obtained by in vivo MR 
spectroscopy at five months after injection of the cells. 
Statistic: * absolute metabolite concentrations from tumour grown from LN-2669GS NCH-1364 
significantly different from those of the same brain region of controls (p < 0.05; **, p < 0.01; 
***, p < 0.001; ****, p < 0.0001); ††† absolute metabolite concentrations from tumour grown 
from LN-2540GS NCH-1365 significantly different from those of the same brain region of 
controls (p < 0.001;  ††††, p < 0.0001). 
Figure 9. Histology of the LN-2669GS and LN-2540GS derived xenografts. For both 
xenografts full brain sections are shown for haematoxylin and eosin stain (H&E) (a, e), and 
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immunohistochemistry for the glial fibrillary acidic protein (GFAP) (b, f), and the human 
specific nucleolin protein (NCL) (c, d, g, h).  
(A) In the LN-2669GS xenograft (NCH-1364), the H&E stained section (a) does not reveal the 
lesion with the exception of a small compact tumour part at the surface of the brain due to reflux 
at the injection site. The GFAP (b) expression (arrow) indicates gliosis induced by infiltrating 
tumour cells. The visualization of the human tumour cells by hNCL (c, d) indicates the highly 
invasive growth properties of the LN-2669GS xenograft NCH-1364 (magnification of the 
marked area (*), scale bar 10 μm). 
(B) The LN-2540GS xenograft is readily visible by H&E, identifying a compact and an invasive 
part (e). Magnification of the marked area (*) in the hNCL immunostained section (h) indicates 
high cell density in the most compact part of the LN-2540GS xenograft NCH-1365 (scale bar 10 
μm). 
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Figure 1. In vivo MRI of LN-2540GS glioma sphere xenograft, 80 days after cell 
injection (pilot study data). Diffusion-weighted images of a mouse brain with LN-
2540GS glioma sphere xenograft acquired with different diffusion times (Δ = 40, 60, 
80, 100, 150, 220 ms) and same b-value (1352 s/mm2). Image (c) shows a slightly better 
tumour contrast compared to others. 
 
 
Figure 2. In vivo MRI of LN-2669GS glioma sphere xenograft, three months after cell 
injection. Upper panel: coronal T2-weighted (a) and diffusion-weighted (b) images of 
the mouse brain with LN-2669GS xenograft NCH-1364, and the calculated ADC (c) 
map. Lower panel: corresponding diffusion tensor maps, MD (d), FA (e) and FA-
modulated directionally encoded colour DEC (f) maps. The lesion (arrow) is barely 
visible on the diffusion-weighted image (b), ADC (c) and DTI maps.  
 
 
Figure 3. In vivo MRI of LN-2540GS glioma sphere xenograft, three months after 
injection of the cells. Upper panel: coronal T2-weighted (a) and diffusion-weighted (b) 
images of the mouse brain with LN-2540GS xenograft NCH-1365, and the calculated 
ADC (c) map. Lower panel: corresponding diffusion tensor maps, MD (d), FA (e) and 
FA-modulated DEC (f) maps. The lesion (arrow) is visible on the diffusion-weighted 
image (b), ADC (c) and DTI maps. 
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Figure 4. In vivo MRI of LN-2669GS glioma sphere xenograft, five months after 
injection of the cells. Upper panel: coronal T2-weighted (a) and diffusion-weighted (b) 
images of the mouse brain with LN-2669GS xenograft NCH-1364, and the calculated 
ADC (c) map. Lower panel: corresponding diffusion tensor maps, MD (d), FA (e) and 
FA-modulated DEC (f) maps. Lesion (arrow) is visible on the diffusion-weighted image 
(b), ADC (c) and DTI maps. Due to the highly invasive and diffuse character of this 
tumour (corresponding histology, Fig. 9) it is difficult to delineate tumour borders. 
 
 
Figure 5. In vivo MRI of LN-2540GS glioma sphere xenograft, five months after 
injection of the cells. T2-weighted (a) and diffusion-weighted (b) images, MD (b), FA 
(c) and FA-modulated DEC maps of a coronal slice from the mouse brain with the LN-
2540GS xenograft NCH-1365. MD, FA and DEC maps, computed after DTI 
reconstruction, show a lesion (indicated by arrow). 
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Figure 6. In vivo MRI of LN-2540GS glioma sphere xenograft (A) and CNR data of 
both xenografts (B), all acquired during the last MRI session (five months after 
injection of the cells). 
(A) Left panel: coronal diffusion-weighted images (a – h) of the mouse brain with LN-
2540GS xenograft NCH-1365. Images are related to the DWI acquisition with b-values 
increasing along the read-out direction. Right panel: corresponding anatomical T2-
weighted image (j) and ADC map (h) of glioma-bearing xenograft. Images were 
acquired 15 days after those shown in Fig. 5. 
Lesion (indicated by arrow and delineated by a dotted line in (g)) is visible on the 
diffusion-weighted images (c – h) and the ADC map. 
(B) The CNR data of LN-2669GS xenograft NCH-1364 and LN-2540GS 
xenograft NCH-1365 as function of b-values obtained in the last MRI session. 
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Figure 7. 1H spectra of the brain from a control mouse (a) and from a tumour derived 
from LN–2669GS, xenograft NCH-1364 (b) and a tumour derived from LN–2540GS, 
xenograft NCH-1365 (c). Spectrum (b) and (c) were acquired 5 months after cells 
injection. Spectra were displayed with a Gaussian filter (0.11). 
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Figure 8. Absolute metabolite concentrations in the tumours grown from LN-2669GS 
and LN-2450GS sphere lines as well as in the same brain region of control obtained by 
in vivo MR spectroscopy at five months after injection of the cells. 
Statistic: * absolute metabolite concentrations from tumour grown from LN-2669GS 
NCH-1364 significantly different from those of the same brain region of controls (p < 
0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001); ††† absolute metabolite 
concentrations from tumour grown from LN-2540GS NCH-1365 significantly different 
from those of the same brain region of controls (p < 0.001;  ††††, p < 0.0001). 
 
 
Figure 9. Histology of the LN-2669GS and LN-2540GS derived xenografts. For 
both xenografts full brain sections are shown for haematoxylin and eosin stain 
(H&E) (a, e), and immunohistochemistry for the glial fibrillary acidic protein 
(GFAP) (b, f), and the human specific nucleolin protein (NCL) (c, d, g, h).  
(A) In the LN-2669GS xenograft (NCH-1364), the H&E stained section (a) does 
not reveal the lesion with the exception of a small compact tumour part at the 
surface of the brain due to reflux at the injection site. The GFAP (b) expression 
(arrow) indicates gliosis induced by infiltrating tumour cells. The visualization of 
the human tumour cells by hNCL (c, d) indicates the highly invasive growth 
properties of the LN-2669GS xenograft NCH-1364 (magnification of the marked 
area (*), scale bar 10 μm). 
(B) The LN-2540GS xenograft is readily visible by H&E, identifying a compact 
and an invasive part (e). Magnification of the marked area (*) in the hNCL 
immunostained section (h) indicates high cell density in the most compact part of 
the LN-2540GS xenograft NCH-1365 (scale bar 10 μm). 
 
